EN IT

Products

Liver Cancer

Colorectal Cancer

Prostate Cancer

Squamous Cell Carcinoma

Literature

Products Literature

updated 14.10.2019 - Group by Marker or Organ

178. Ali LH, Higazi AM, Moness HM, Farag NM, Saad ZM, Moukareb HA, Soliman W, El Sagheer G, Abd El Hamid SR, Abdl Hamid H. Clinical significances and diagnostic utilities of both miR-215 and squamous cell carcinoma antigen-IgM versus alpha-fetoprotein in Egyptian patients with hepatitis C virus-induced hepatocellular carcinoma.. Clin Exp Gastroenterol.. 12:51-66. 2019. doi: 10.2147/CEG.S179832
177. Antonelli A, Francavilla S, Gallotta A, Da Pozzo LF, Ferretti S, Sigala S, Simeone C, Mirone V, Artibani W, Porreca A. Actual evidences and future perspectives about the role of iXip® in the diagnosis of prostate cancer: a narrative review.. Minerva Urol Nefrol. . 2019. doi: 10.23736/S0393-2249.19.03329-0
176. Bettini S, Bordigato E, Milan G, Dal Pra’ C, Favaretto F, Belligoli A, Sanna M, Serra R, Foletto M, Prevedello L, Busetto L, Fassina G, Vettor R, Fabris R. SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy. Obes Facts. 12:291–306. 2019. doi: 10.1159/000499717
175. Turato C, Fornari F, Pollutri D, Fassan M, Quarta S, Villano G, Ruvoletto M, Bolondi L, Gramantieri L, Pontisso P. MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma.. J Clin Med. 8(2). 2019. doi: 10.3390/jcm8020171
174. Turato C, Scarpa M, Kotsafti A, Cappon A, Quarta S, Biasiolo A, Cavallin F, Trevellin E, Guzzardo V, Fassan M, Chiarion-Sileni V, Castoro C, Rugge M, Vettor R, Scarpa M, Pontisso P. Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity.. Cancer Sci.. 110(5):1552-1563. 2019. doi: 10.1111/cas.13986
173. Bui Huu H, Ha Thuc N, Thi Le HP, Thi Thanh TD, Luong Bac A, Tiribelli C, Pontisso P, Gallotta A, Paneghetti L, Fassina G. Characterization of SCCA-IgM as a biomarker of liver disease in an Asian cohort of patients. Scand J Clin Lab Invest. ePub:1-7. 2018. doi: 10.1080/00365513.2018.1432072
172. Cagnin M, Biasiolo A, Gallotta A, Martini A, Ruvoletto M, Quarta S, Fasolato S, Angeli P, Fassina G, Pontisso P. Low levels of squamous cell carcinoma antigen–IgM complexes in serum are predictors of better survival in patients with liver cirrhosis. Dig Liver Dis. 50(S1):42. 2018. doi: 10.1016/j.dld.2018.01.039
171. Chang-Hai Liu, Antonio Gil-Gómez, Javier Ampuero, Manuel Romero-Gómez. Diagnostic accuracy of SCCA and SCCA-IgM for hepatocellular carcinoma: A meta-analysis. Liver Int.. 38:1820–1831. 2018. doi: 10.1111/liv.13867
170. Gallotta A, Paneghetti L, Mrázová V, Bednárová A, Kružlicová D, Frecer V, Miertus S, Biasiolo A, Martini A, Pontisso P, Fassina G. Development of a novel diagnostic algorithm to predict NASH in HCV-positive patients. Int J Biol Markers. eISSN 1724-6008. 2018. doi: 10.1177/1724600817753577
169. Galosi AB, Dell'Atti L, Bertaccini A, Gion M, Francavilla S, Ferretti S, Maestroni U, Gallotta A, Parrozzani C, Paneghetti L, Fassina G. Clinical evaluation of the iXip index to reduce prostate re-biopsies. Cancer Treat Res Comm. 16:59-63. 2018. doi: 10.1016/j.ctarc.2018.07.001
168. Gringeri E, Di Giunta M, Biasiolo A, Ruvoletto M, Villano G, Zarantonello L, Pontisso P, Cillo U. Serum and bile squamous cell carcinoma antigen detection: a new prognostic marker in patients with perihilar cholangiocarcinoma. Dig Liver Dis. 50(S1):40. 2018. doi: 10.1016/j.dld.2018.01.116
167. Maier S, Crocè L, Buonocore MR, Pilon C, Fargion S, Vettor R, Sechi LA, Donnini D, Pagano C, Valenti L, Soardo G. Role of SERPINB3 like serological and molecular biomarker into NASH development and progression. Dig Liver Dis. 50(S1):18. 2018. doi: 10.1016/j.dld.2018.01.037
166. Paneghetti L, Gallotta A, Parrozzani C, Fassina G. Biomarkers development for early detection of cancer: Reducing the burden of cancer in the ageing society. EuroBiotech J. 2(1):30-34. 2018. doi: 10.2478/ebtj-2018-0005
165. Raggi C, Cappon A, Correnti M, Andersen JB, Forti E, Cavalloni G, Torchio E, Pontisso P, Marra F. The protease-inhibitor SerpinB3 outlines a stem-like subset in human cholangiocarcinoma. Dig Liver Dis. 50(S1):47. 2018. doi: 10.1016/j.dld.2018.01.049
164. Gallotta A, Giannarini G, Laurini L, Zani D, Garbeglio A, Guazzieri S, Plebani M, Fassina G, Zattoni F. Clinical validation of the iXip index in avoiding unnecessary prostate biopsy: results from a prospective multicenter study involving 426 patients. Cancer Treat Res Comm. 10:40-45. 2017. doi: 10.1016/j.ctarc.2017.01.002
163. Gringeri E, Di Giunta M, Biasiolo A, D'Amico FE, Fasolo E, Pontisso P, Cillo U. Serum and bile squamous cell carcinoma antigen 1 (SCCA1) detection: a new diagnostic approach in patients with perihilar cholangiocarcinoma (pCCA). The Liver Meeting-American Association for the Study of Liver Diseases (AASLD). Washington DC, USA. 2017. doi: 10.1002/hep.29501
162. Guarino M, Di Costanzo GG, Gallotta A, Tortora R, Paneghetti L, Auriemma F, Tuccillo C, Fassina G, Caporaso N, Morisco F. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients. Scand J Clin Lab Invest. 77(6):448-453. 2017. doi: 10.1080/00365513.2017.1336569
161. Maddalo G, Fassan M, Cardin R, Piciocchi M, Marafatto F, Rugge M, Zaninotto G, Pozzan C, Castoro C, Ruol A, Biasiolo A, Farinati F. Squamous Cellular Carcinoma Antigen serum determination as a biomarker of Barrett esophagus and esophageal cancer: a phase III study. J. Clin. Gastroenterol.. ePub. 2017. doi: 10.1097/MCG.0000000000000790
160. Ricco G, Cavallone D, Pontisso P, Fassina G, Gallotta A, Colombatto P, Oliveri F, Romagnoli V, Coco B, Salvati A, Bonino F, Brunetto MR. In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)-IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy. Dig Liver Dis. 49(1):e48. 2017. doi: 10.1016/j.dld.2017.01.099
159. Biasiolo A, Martini A, Gallotta A, Fassina G, Pontisso P. Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as biomarker in liver disease: biological aspects and clinical applications. Biom Liver Dis. 1-22. 2016. doi: 10.1007/978-94-007-7742-2_15-1
158. Biasiolo A, Trotta E, Fasolato S, Ruvoletto M, Martini A, Gallotta A, Fassina G, Angeli P, Gatta A, Pontisso P. Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. Dig Liver Dis. 48(2):197-202. 2016. doi: 10.1016/j.dld.2015.10.022
157. Gil-Gómez A, Ampuero J, Gallego-Durán R, Fassina G, Pontisso P, Romero-Gomez M. SCCA-IgM helps to identify patients at risk of long-term hepatocellular carcinoma. Hepatology. 64(S1):656A. 2016. doi: 10.1002/hep.28799
156. Biasiolo A, Martini A, Pontisso P. New biomarkers for clinical management of hepatitis C virus infected patients. World J Clin Infect Dis. 5(4):59-66. 2015. doi: 10.5495/wjcid.v5.i4.59
155. Crescenzi M, Tessari A, Biasiolo A, Padoan A, Gallotta A, Fassina G, Panciatichi C, Rossetto O, Pontisso P, Basso D, Plebani M. Analytical Validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma. Anal Methods. 7(2):629-637. 2015. doi: 10.1039/C4AY02495H
154. Gallotta A, Mràzovà V, Bednàrovà A, Kruzlicovà D, Frecer V, Miertus S, Fattovich G, Biasiolo A, Martini A, Ieluzzi D, Guido M, Pontisso P, Fassina G. A novel algorithm based on serum SCCA-IgM determination combined with common clinical data improves prediction of histological NASH. Dig Liver Dis. 47(S3):e226. 2015. doi: 10.1016/j.dld.2015.07.025
153. Liu J, Gao Y, Yang B, Jia X, Zhai D, Li S, Zhang Q, Jing L, Wang Y, Du Z, Wang Y. Overexpression of Squamous Cell Carcinoma Antigen 1 Is Associated with the Onset and Progression of Human Hepatocellular Carcinoma. Arch. Med. Res. 46(2):133-141. 2015. doi: 10.1016/j.arcmed.2015.03.003
152. Maddalo G, Fassan M, Cardin R, Piciocchi M, Marafatto F, Rugge M, Zaninotto G, Pozzan C, Castoro C, Ruol A, Farinati F. Squamous cellular carcinoma antigen serum determination as a biomarker of Barrett's esophagus and esophageal cancer: a phase III study. UEG Journal. 3:118. 2015. doi: 10.1177/2050640615601611
151. Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients. J Viral Hepat. 22(10):800-808. 2015. doi: 10.1111/jvh.12394
150. Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen immunoglobulins M to monitor chronic hepatitis C. World J Hepatol. 7(29):2913-2919. 2015. doi: 10.4254/wjh.v7.i29.2913
149. Montagnana M, Danese E, Lippi G. Squamous cell carcinoma antigen in hepatocellular carcinoma: ready for the prime time?. Clin Chim Acta. 445:161-166. 2015. doi: 10.1016/j.cca.2015.03.031
148. Morisco F, Guarino M, Di Costanzo GG, Gallotta A, Fassina G, Tortora R, Tuccillo C, Granata R, Loperto I, Auriemma F, Caporaso N. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients. J Hepatol. 62(S2):S450. 2015. doi: 10.1016/S0168-8278(15)30582-1
147. Pieri G, Marenco S, Lantieri F, Baldissarro I, Bruzzone L, Fazio V, Labanca S, Sammito G, Savarino V, Picciotto A. Serum SCCA-IgM can predict the development of HCC in patients with HCV-cirrhosis. Dig Liver Dis. 47(S1):e59. 2015. doi: 10.1016/j.dld.2015.01.129
146. Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 21(37):10573-10583. 2015. doi: 10.3748/wjg.v21.i37.10573
145. Tzouvadaki I, Parrozzani C, Gallotta A, De Micheli G, Carrara S. Memristive Biosensors for PSA-IgM Detection. BioNanoSci. 5(4):189-195. 2015. doi: 10.1007/s12668-015-0179-4
144. Zhang J, Shao C, Zhou Q, Zhu Y, Zhu J, Tu C. Diagnostic accuracy of serum squamous cell carcinoma antigen and serum squamous cell carcinoma antigen-immunoglobulin M for hepatocellular carcinoma: A meta-analysis. Mol Clin Oncol. 3(5):1165-1171. 2015. doi: 10.3892/mco.2015.600
143. Biasiolo A, Trotta E, Fasolato S, Tono N, Ruvoletto M, Martini A, Terrin L, Fassina G, Angeli P, Gatta A, Pontisso P. P569 SCCA-IgM is predictive of hepatocellular carcinoma development in patients with hcv cirrhosis. A prospective study. J Hepatol. 60(1):S259. 2014. doi: 10.1016/S0168-8278(14)60731-5
142. Fadini GP, Albiero M, Millioni R, Poncina N, Rigato M, Scotton R, Boscari F, Brocco E, Arrigoni G, Villano G, Turato C, Biasiolo A, Pontisso P, Avogaro A. The molecular signature of impaired diabetic wound healing identifies serpinB3 as a healing biomarker. Diabetologia. 57(9):1947-56. 2014. doi: 10.1007/s00125-014-3300-2
141. Gallotta A, Fassina G. Optical Biochips for Biomarkers-IgM Complexes Codetermination in Hepatocellular Carcinoma. . In Sensors (pp. 85-88). Springer New York. 2014.
140. Guarino M, Di Costanzo G G, Gallotta A, Fassina G, Tortora R, Tuccillo C, Auriemma F, Caporaso N, Morisco F. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients. Dig Liver Dis. 46(S4):e137. 2014. doi: 10.1016/j.dld.2014.08.020
139. Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. Genotype 3 and circulating SCCA-IgM are independently associated with histological features of NASH in HCV infected patients. Dig Liver Dis. 46(51):e26. 2014. doi: 10.1016/j.dld.2014.01.061
138. Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. P837 Genotype 3 and circulating SCCA-IgM are independently associated with histological features of nash in hcv infected patients. J Hepatol. 60(1):S350-S351. 2014. doi: 10.1016/S0168-8278(14)60998-3
137. Mossad NA, Mahmoud EH, Osman EA, Mahmoud SH, Shousha HI. Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IgM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma. Tumour Biol. 35(11):11559-64. 2014. doi: 10.1007/s13277-014-2467-y
136. Pontisso P. Role of SERPINB3 in hepatocellular carcinoma. Ann Hepatol. 13(6):722-727. 2014.
135. Pozzan C, Cardin R, Piciocchi M, Cazzagon N, Maddalo G, Vanin V, Giacomin A, Pontisso P, Cillo U, Farinati F. Diagnostic and Prognostic Role of SCCA-IgM Serum Levels in Hepatocellular Carcinoma (Hcc). J Gastroenterol Hepatol. 29(8):1637-44. 2014. doi: 10.1111/jgh.12576
134. Biasiolo A, Tono N, Zaninotto M, Merkel C, Fassina G, Plebani M, Gatta A, Pontisso P. Specificity of squamous cell carcinoma antigen (SCCA)-IgM detection in patients with HCV infection and rheumatoid factor seropositivity. J Med Virol. 85(6):1005-8. 2013. doi: 10.1002/jmv.23493
133. Gallotta A, Ziglioli F, Ferretti S, Maestroni U, Moretti M, Aloe R, Gnocchi C, Di Palo M, Fassina G. A novel algorithm for the prediction of prostate cancer in clinically suspected patients. Cancer Biomark. 13(4):227-34. 2013. doi: 10.3233/CBM-130357
132. Goc S, Jankovic M. Evaluation of Molecular Species of Prostate-Specific Antigen Complexed with Immunoglobulin M in Prostate Cancer and Benign Prostatic Hyperplasia. Dis. Markers. 35(6):847-855. 2013. doi: 10.1155/2013/923819
131. Matteucci C, Sorrentino R, Bellis L, Ettorre GM, Svicher V, Santoro R, Vennarecci G, Biasiolo A, Pontisso P, Scacciatelli D, Beneduce L, Sarrecchia C, Casalino P, Bernardini S, Pierimarchi P, Garaci E, Puoti C, Rasi G. Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis. Hepatol. Res. 44(9):1008-18. 2013. doi: 10.1111/hepr.12239
130. Morisco F, Di Costanzo GG, Guarino M, Tortora R, Loperto I, Auriemma F, Ferraiuoli C, Tuccillo C, Beneduce L, Caporaso N . SCCA-IgM: a biomarker to monitor the outcome of therapy with sorafenib in advanced HCC. Dig Liver Dis. 45:S217-18. 2013. doi: 10.1016/S1590-8658(13)60622-2
129. Morisco F, Di Costanzo GG, Guarino M, Tortora R, Loperto I, Clery E, Auriemma F, Tuccillo C, Beneduce L, Caporaso N. Circulating SCCA-IgM complex is able to monitor the success of loco-regional therapy in HCC patients. Dig Liver Dis. 45:S218. 2013. doi: 10.1016/S1590-8658(13)60623-4
128. Morisco F, Di Costanzo GG, Guarino M, Tortora R, Loperto I, Tuccillo C, Ferraiuoli C, Beneduce L, Auriemma F, Caporaso N. Su1001 Circulating Scca-IgM Complex Is an Useful Biomarker to Monitor HCC Therapy. Gastroenterology. 144:S-991. 2013. doi: 10.1016/S0016-5085(13)63676-8
127. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 39(4):410-33. 2012. doi: 10.1053/j.seminoncol.2012.05.001
126. Biasiolo A, Tono N, Ruvoletto M, Quarta S, Turato C, Villano G, Beneduce L, Fassina G, Merkel C, Gatta A, Pontisso P. IgM-linked SerpinB3 and SerpinB4 in sera of patients with chronic liver disease. PLoS ONE. 7(7):e40658. 2012. doi: 10.1371/journal.pone.0040658
125. Buccione D, Fatti G, Gallotta A, Loggi E, Di Donato R, Testa L, Saitta C, Santi V, Di Micoli A, Erroi V, Fazio V, Picciotto A, Biasiolo A, Degos F, Pontisso P, Raimondo G, Trevisani F. Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis. OJGas. 2(2):56-61. 2012. doi: 10.4236/ojgas.2012.22012
124. Calabrese F, Lunardi F, Balestro E, Marulli G, Perissinotto E, Loy M, Nannini N, Valente M, Saetta M, Agostini C, Rea F. Serpin B4 isoform overexpression is associated with aberrant epithelial proliferation and lung cancer in idiopathic pulmonary fibrosis. Pathology. 44(3):192-198. 2012. doi: 10.1097/PAT.0b013e3283511b61
123. Fransvea E, Trerotoli P, Sacco R, Bernabucci V, Milella M, Napoli N, Mazzocca A, Renna E, Quaranta M, Angarano G, Villa E, Antonaci S, Giannelli G. SCCA-IC serum levels are predictive of clinical response in HCV chronic hepatitis to antiviral therapy: a multicentric prospective study. J Viral Hepat. 19:704-710. 2012. doi: 10.1111/j.1365-2893.2012.01604.x
122. Gallotta A, Orzes E, Fassina G. Biomarkers Quantification with Antibody Arrays in Cancer Early Detection. Clin Lab Med. 32(1):33-45. 2012. doi: 10.1016/j.cll.2011.11.001
121. Morisco F, Guarino M, Tortora R, Donnarumma L, Loperto I, Camera S, Mariniello A, Tuccillo C, Beneduce L, Di Costanzo GG, Caporaso N . Serum Levels of SCCA-IgM are related to the efficacy of HCC treatments. Dig Liver Dis. 44(S2):S135. 2012. doi: 10.1016/S1590-8658(12)60373-9
120. Pozzan C, Cardin R, Pichiocchi M, Cazzagon N, Sergio A, Vanin V, Giacomin A, Pontisso P, Cillo U, Farinati F. Prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC). Dig Liver Dis. 44(S2):S141-S142. 2012. doi: 10.1016/S1590-8658(12)60393-4
119. Turato C, Buendia MA, Fabre M, Redon MJ, Branchereau S, Quarta S, Ruvoletto M, Perilongo G, Grotzer MA, Gatta A, Pontisso P. Over-expression of SERPINB3 in hepatoblastoma: a possible insight into the genesis of this tumour?. Eur J Cancer. 48(8):1219-26. 2012. doi: 10.1016/j.ejca.2011.06.004
118. Zorzetto V, Maddalo G, Rugge M, Parente P, Zaninotto G, Ruol A, Biasiolo A, Zanatta L, Farinati F. SCCA-IgM determination in Barrett's esophagus and esophageal cancer might regulate endoscopic follow-up schedule. Dig Liver Dis. 44(S2):S151. 2012. doi: 10.1016/S1590-8658(12)60420-4
117. Bertino G, Neri S, Bruno CM, Ardiri AM, Calvagno GS, Malaguarnera M, Toro A, Malaguarnera M, Clementi S, Bertino N, Di Carlo I. Diagnostic and prognostic value of alpha-fetoprotein, des-gamma-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med. 102:363-71. 2011.
116. Biasiolo A, Tono N, Briarava M, Beneduce L, Fassina G, Farinati F, Giacomin A, Matteucci C, Sorrentino R, Nitti D, Gatta A , Pontisso P. Improved diagnostic accuracy for HCC using a combination of IgM-linked biomarkers. Dig Liver Dis. 43(S2):S91. 2011. doi: 10.1016/S1590-8658(11)60081-9
115. Buccione D, Fatti G, Gallotta A, Loggi E, Di Donato R, Testa L, Saitta C, Santi V, Di Micoli A, Fazio V, Picciotto A, Biasiolo A, Pontisso P, Raimondo G, Trevisani F. Serum SCCA-IgM as a predictor of hepatocellular carcinoma (HCC) in patients with liver cirrhosis. Dig Liver Dis. 43(S2):S95. 2011. doi: 10.1016/S1590-8658(11)60094-7
114. Fassina G. Le nanotecnologie nella diagnosi e nella terapia. ICF. 2:34-7. 2011.
113. Giulianelli R, Albanesi L, Brunori S, Gentile B, Mavilla L, Pisanti F, Mirabile G, Shestani T, Attisani F, Schettini M, Damian M, Cervo S, Steffan A. The use of PSA-IgM in the diagnosis of prostate cancer. Urology. 78(S3A):S304. 2011. doi: 10.1016/j.urology.2011.07.948
112. Gomiero C, Pengo P, Gallotta A, Biasiolo A, Tono N, Gatta A, Pontisso P, Matteucci C, Fassina G, Beneduce L. Improved detection of HCC by co-determination of IgM anti-AFP antibodies and AFP-IgM immune complexes. J Hepatol. 54:S382. 2011.
111. Jiang J, Wu C, Shen Y, Xu B, Zheng X, Li X, Xu N. Clinical Application of Determining Serum AFP-IgM Complexes for Diagnosis of Small Hepatocellular Carcinoma. Anticancer Res. 31:687-92. 2011.
110. Kojima T, Matsui T, Yasunobu Fujimitsu Y, Hiroshi Kojima H, Uno H, Hiramatsu K, Inagaki H, Oda K, Ishiyama A, Iwata N, Nakayama G, Kodera Y. Titration of serum CEA, p53 antibodies and CEA-IgM complexes in 142 patients with colorectal cancer and 150 healthy blood donors. Ann Cancer Res Therap. 19(1):15-19. 2011. doi: 10.4993/acrt.19.15
109. Krygier R, Stefaniuk P, Mikula T, Dusza M, Jablonowska M, Cianciara J, Wasyluk H, Wiercinska-Drapalo A. Usefulness of alpha-fetoprotein as circulating Immune Complexes (AFP-IC) in the diagnosis of hepatocellular carcinoma in cirrhotic patients. Exp Clin Hep. 7:44-48. 2011.
108. Plebani M, Wu AH. Circulating macrocomplexes: old wine in new bottles?. Clin Chem Lab Med. 49(5):759-60. 2011. doi: 10.1515/cclm.2011.150
107. Pozzan C, Cardin R, Cazzagon N, Picciocchi M, vanin V, Giacomin A, Sergio P, Pontisso P, Farinati F. Diagnostic and prognostic role of SCCA-IgM in hepatocellular carcinoma (HCC). J Hepatol. 54: S101. 2011. doi: 10.1016/S0168-8278(11)60246-8
106. Prayer-Galetti T, Vianello F, Secco S, Plebani M, Liverani A, Laurini L, Fulcoli V, Lorenzo R, Garbeglio A, Zani D, Cosciani Cunico S, Zattoni F. Il dosaggio dell'immunocomplesso PSA-IgM e la conseguente valutazione dell'indice iXip nella diagnostica del carcinoma prostatico. 84° Congresso SIU. Rome, Italy. 2011.
105. Schmilovitz-Weiss H, Tobar A, Halpern M, Levy I, Shabtai E, Ben-Ari Z. Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: A historical prospective study. Diagn Pathol. 6:121. 2011. doi: 10.1186/1746-1596-6-121
104. Turato C, Biasiolo A, Pengo P, Frecer V, Quarta S, Fasolato S, Ruvoletto M, Beneduce L, Zuin J, Fassina G, Gatta A, Pontisso P. Increased antiprotease activity of the SERPINB3 polymorphic variant SCCA-PD. Exp Biol Med. 236:281-90. 2011.
103. Turato C, Buendia MA, Fabre M, Redon MJ, Branchereau S, Quarta S, Ruvoletto MG, Perilongo G, Grotzer MA, Gatta A, Pontisso P. Over-expression of SERPINB3 in hepatoblastoma: a possible insight into the genesis of this tumor?. Dig Liver Dis. 43(S2):S66. 2011. doi: 10.1016/S1590-8658(11)60005-4
102. Zorzetto V, Rugge M, Parente P, Zaninotto G, Castoro M, Ruol A, Maddalo G, Zanatta L, Farinti F. SCCA-IgM and CEA-IgM in Barrett's esophagus and esophageal cancers. Dig Liver Dis. 43:S156. 2011.
101. Giannini EG, Basso M, Bazzica M, Contini P, Marenco S, Savarino V, Picciotto A. Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. J Viral Hepat. 17(8):563-568. 2010. doi: 10.1111/j.1365-2893.2009.01217.x
100. Kojima T, Yoshikawa K, Matsui T, Kodera Y, Kojima H. Detection of circulating CEA-IgM complexes in early stage gastric cancer. Ann Cancer Res Therap. 18(2):69-72. 2010. doi: 10.4993/acrt.18.69
99. Pengo P, Veggiani G, Rattanemanee K, Gallotta A, Beneduce L, Fassina G. Solid Phase Synthesis of Protein Conjugates. J Mol Recognit. 23:551-8. 2010.
98. Quarta S, Vidalino L, Turato C, Ruvoletto MG, Calabrese F, Valente M, Cannito S, Fassina G, Parola M, Gatta A, Pontisso P. SERPINB3 induces epithelial-mesenchymal transition. J Pathol. 221(3):343-56. 2010. doi: 10.1002/path.2708
97. Savitskaya Y, Rico G, Linares L, Gonzalez R, Tellez R, Estrada E, Marin N, Martinez E, Alfaro A, Ibarra C. Circulating Natural IgM Antibodies Against Angiogenin in the Peripheral Blood Sera of Patients with Osteosarcoma as Candidate Biomarkers and Reporters of Tumorigenesis. Biomark Cancer. 2:65-78. 2010. doi: 10.4137/BIC.S6040
96. Stefaniuk P, Janusz Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 16:418-24. 2010.
95. Stefaniuk P, Krygier R, Dusza M, Jablonowska M, Mikula T, Dabrowska M, Cianciara J, Wiercinska-Drapalo A. Do we have more predictive HCC biomarkers? Usefulness of new generation of HCC biomarkers in immune complexes with immunoglobulins of the IgM class. Exp Clin Hep. 6:AB18-18. 2010.
94. Teofanescu I, Gologan E, Stefanescu G, Balan G. Surveillance of cirrhosis for hepatocellular carcinoma clinical validation of new serological biomarkers for improved hepatocellular carcinoma diagnosis. Rev Med Chir Soc Med Nat Iasi. 114:39-46. 2010.
93. Turato C, Calabrese F, Biasiolo A, Quarta S, Ruvoletto MG, Tono N, Paccagnella D, Fassina G, Merkel C, Harrison TJ, Gatta A, Pontisso P. SERPINB3 modulates TGF-beta expression in chronic liver disease. Lab Invest. 90(7):1016-23. 2010. doi: 10.1038/labinvest.2010.55
92. Veggiani G, Zuin J, Beneduce L, Pengo P, Fassina G. Combinatorial semisynthesis of biomarker-IgM complexes. J Biomol Screen. 15:1274-80. 2010.
91. Verna M, Pengo P, Gallotta A, Zani D, Costa S, Leon A, Gion M, Fassina G, Beneduce L. Improved detection of low grade prostate cancer by PSA-IgM assessment. Anticancer Res. 30:1486-7. 2010.
90. Villano G, Quarta S, Ruvoletto MG, Turato C, Vidalino L, Biasiolo A, Tono N, Lunardi F, Calabrese F, Dall'olmo L, Dedja A, Fassina G, Gatta A, Pontisso P. Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice. Int J Mol Med. 25(1):137-43. 2010. doi: 10.3892/ijmm_00000323
89. Yim S, Chung Y. An Overview of Biomarkers and Molecular Signatures in HCC. Cancers (Basel). 2:809-23. 2010. doi: 10.3390/cancers2020809
88. Zani D, Costa S, Beneduce L, Fassina G, Simeoni C, Cosciani Cunico S. Immunità e cancro: ruolo degli immunocomplessi PSA-IgM nel cancro della prostata. Urologia. 77:1-3. 2010.
87. Zani D, Costa S, Pettenò A, Simeone C, Cosciani Cunico S, Leon AE, Gion M, Fassina G, Beneduce L. Combined role of serum assays of PSA-IgM and PSA for the diagnosis of prostate cancer. Anticancer Res. 30:1496-7. 2010.
86. Zuin J, Veggiani G, Pengo P, Gallotta A, Biasiolo A, Tono N, Gatta A, Pontisso P, Toth R, Cerin D, Frecer V, Meo S, Gion M, Fassina G, Beneduce L. Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis. Clin Chem Lab Med. 48(2):217-23. 2010. doi: 10.1515/CCLM.2010.044
85. Biasiolo A, Tono N, Beneduce L, Zuin J, Fassina G, Meo S, Paccagnella L, Mazzucco M, Farinati F, Giacomin A, Vanin V, Aldino M, Miola E, Donà S, Matteucci C, Sorrentino R, Rasi G, Gatta A, Pontisso P. Osteopontin-IgM as a marker for the diagnosis of hepatocellular carcinoma. Int J Biol Markers. 24:206. 2009.
84. Biasiolo A, Tono N, Franzosi L, Beneduce L, Zuin J, Fassina G, Meo S, Paccagnella D, Mazzucco M, Farinati F, Giacomin A, Vanin V, Aldinio M, Miola E, Donà S, Gatta A, Pontisso P. Osteopontin-IgM in the diagnosis of HCC. Dig Liver Dis. 41(5):A4-A5. 2009. doi: 10.1016/j.dld.2009.02.017
83. Biasiolo A, Tono N, Quarta S, Beneduce L, Gatta A, Fassina G, Pontisso P. SCCA1-IgM and SCCA2-IgM compared with total SCCA-IgM for diagnosis of hepatocellular carcinoma. Int J Biol Markers. 24:205. 2009.
82. Bucca E, Beneduce L, Leon A, Fabricio A, Michilin S, Meo S, Vitale M, Steffan A, Durante C, Bellucco C, Rizzo A, Berlanda G, Perasole A, Zampieri F, Zuin J, Veggiani G, Fassina G, Gion M. The usefulness of the combination of free CA 15.3 and CA 15.3-IgM complexes for breast cancer diagnosis. Int J Biol Markers. 24:193. 2009.
81. Cannito S, Turato C, Quarta S, Colombatto S, Biasiolo A, Pontisso P, Parola M. Hypoxia up-regulates SERPINB3 in HEPG2 cells: a redox sensitive event related to epithelial to mesenchymal transition and invasiveness. Dig Liver Dis. 41(3):A31-A32. 2009. doi: 10.1016/j.dld.2008.12.066
80. Cannito S, Turato C, Quarta S, Paternostro C, Colombatto S, Biasiolo A, Pontisso P, Parola M. Serpin B3 up-regulation by hypoxia in HepG2 cells: A redox sensitive, Ras/ERK and PI3-K mediated event related to invasiveness and epithelial to mesenchymal transition. Dig Liver Dis. 41(3):A19. 2009. doi: 10.1016/j.dld.2009.02.046
79. Carrara S, Bhalla V, Stagni C, Benini C, Ferretti A, Valle F, Gallotta A, Riccio B, Samorì B. Label-free cancer markers detection by capacitance biochip. Sens Actuators B Chem. 136(1):163-172. 2009. doi: 10.1016/j.snb.2008.09.050
78. Gallotta A, Pengo P, Beneduce L, Fassina G. Combinatorial approaches in cancer early detection. Drug Design and Discovery for Developing Countries (Eds. Megnassan E, Owono Owono L, Miertus S) ICS-UNIDO. 206-18. 2009.
77. Gallotta A, Zuin J, Veggiani G, Pengo P, Biasiolo A, Tono N, Gatta A, Pontisso P, Fassina G, Beneduce L. Combining SCCA-IgM and AFP-IgM levels increases accuracy of hepatocellular carcinoma detection. Dig Liver Dis. 41(5):A15. 2009. doi: 10.1016/j.dld.2009.02.038
76. Gallotta A, Zuin J, Veggiani G, Pengo P, Leon A, Gion M, Biasiolo A, Tono N, Gatta A, Pontisso P, Fassina G, Beneduce L. Combination of biomarkers-IgM by logistic regression improves diagnostic accuracy in hepatocellular carcinoma. Int J Biol Markers. 24:208. 2009.
75. Hayashi M, Tomita S, Fujimori T, Nagata H, Kubota K, Shoda A, Tada K, Kosaka N, Fukasawa I, Inaba N. Retrorectal epidermoid cyst with unusually elevated serum SCC level, initially diagnosed as an ovarian tumor. Rare Tumors. 1(2):e21. 2009. doi: 10.4081/rt.2009.e21
74. Jingting J, Changping W, Ning X, Vibei Z, Jun W, Mei J, Bin X, Peter N, Xueguan Z. Clinical evaluation of serum alpha-fetoprotein-IgM immune complexes on the diagnosis of primary hepatocellular carcinoma. J Clin Lab Anal. 23(4):213-8. 2009. doi: 10.1002/jcla.20321
73. Kojima T, Yoshikawa K, Matsui T, Kodera Y, Kojima H. Titration of serum CEA, p53 antibodies and CEA-IgM complexes in patients with colorectal cancer. Mol Med Report. 2(3):477-80. 2009. doi: 10.3892/mmr_00000124
72. Kumar M, Sarin SK. Biomarkers of diseases in medicine. Current Trends in Science. 403-417. 2009.
71. Lunardi F, Pontisso P, Rea F, Villano G, Gnoato M, Agostini C, Calabrese F. Overexpression of Serpin B3 promotes epithelial instability in bleomicyn lung injury. Eur Respir J. 54:E3092. 2009.
70. Lunardi F, Pontisso P, Rea F, Villano G, Gnoato M, Agostini C, Valente M, Calabrese F. Serpin B3 transgenic mice are more susceptible to lung fibrosis and epithelial proliferation. Virchows Arch. 455(S1):S84. 2009. doi: 10.1007/s00428-009-0805-z
69. Matteucci C, Sorrentino R, Ettorre G, Bellis L, Antenucci A, Beneduce L, Santoro R, Vennarecci G, Zuin J, Biasiolo A, Pontisso P, Pierimarchi P, Puoti C, Rasi G. Circulating survivin-IgM is a novel candidate biomarker of cirrhosis and increases with child score in patients affected by liver disease. Int J Biol Markers. 24:210. 2009.
68. Matteucci C, Sorrentino R, Ettorre G, Bellis L, Antenucci A, Beneduce L, Santoro R, Vennarecci G, Zuin J, Pierimarchi P, Puoti C, Rasi G. Survivin-IgM immuno complex: a novel candidate biomarker of cirrhosis to monitor patients progression towards hepatocellular carcinoma. Dig Liver Dis. 41(5):A13. 2009. doi: 10.1016/j.dld.2009.02.035
67. Quarta S, Vidalino L, Turato C, Ruvoletto M, Calabrese F, Fassina G, Gatta A, Pontisso P. SERPINB3 induces epithelial mesenchymal transition. Dig Liver Dis. 41(5):A1-A2. 2009. doi: 10.1016/j.dld.2009.02.012
66. Quarta S, Villano G, Turato C, Biasiolo A, Vidalino L, Ruvoletto M, Tono N, Calabrese F, Nicolosi L, Bernardi P, Gatta A, Pontisso P. Hepatic progenitor cells overexpress SERPINB3 in a mouse model of fulminant hepatitis. J Hepatol. 50:S312. 2009. doi: 10.1016/S0168-8278(09)60858-8
65. Sheng SL, Wang Q, Huang G, Yu B, Qin WX. Simultaneous determination of alpha-fetoprotein immune complexes and alpha-fetoprotein concentration in hepatocellular carcinoma using dual-label time-resolved immunofluorometric assays. J Clin Lab Anal. 23(3):179-85. 2009. doi: 10.1002/jcla.20316
64. Trerotoli P, Fransvea E, Angelotti U, Antonaci G, Lupo L, Mazzocca A, Mangia A, Antonaci S, Giannelli G. Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. Mol Cancer. 8:29. 2009. doi: 10.1186/1476-4598-8-29
63. Turato C, Calabrese F, Biasiolo A, Quarta S, Ruvoletto M, Tono N, Franzosi L, Paccagnella D, Fassina G, Gatta A, Pontisso P. SERPINB3 and TGF-beta1 in chronic liver disease. Dig Liver Dis. 41(3):A13-A14. 2009. doi: 10.1016/j.dld.2008.12.030
62. Turato C, Calabrese F, Biasiolo A, Quarta S, Ruvoletto M, Tono N, Franzosi L, Paccagnella L, Fassina G, Gatta A. SERPINB3 and TGF-beta1 correlation in chronic liver disease. J Hepatol. 50:S117. 2009. doi: 10.1016/S0168-8278(09)60302-0
61. Turato C, Ruvoletto MG, Biasiolo A, Quarta S, Tono N, Bernardinello E, Beneduce L, Fassina G, Cavalletto L, Chemello L, Merkel C, Gatta A, Pontisso P. Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease. Dig Liver Dis. 41(3):212-216. 2009. doi: 10.1016/j.dld.2008.06.001
60. Vidalino L, Doria A, Quarta S, Zen M, Gatta A, Pontisso P. SERPINB3, apoptosis and autoimmunity. Autoimmun Rev. 9(2):108-12. 2009. doi: 10.1016/j.autrev.2009.03.011
59. Villano G, Turato C, Campagna F, Schiff S, Calabrese F, Gatta A, Amodio P, Pontisso P. Role of microglial activation via SERPINB3 in experimental acute hepatic encephalopathy. J Hepatol. 50:S71. 2009. doi: 10.1016/S0168-8278(09)60170-7
58. Zani D, Costa S, Gatti L, Pesenti N, Pettenò A, Zambolin T, Simeone C, Cunico S, Leon A, Zuin J, Pengo P, Fassina G, Beneduce L. The association of PSA-IgM and total PSA improves the diagnosis of prostate cancer. Int J Biol Markers. 24:212. 2009.
57. Zuin J, Veggiani G, Pengo P, Gallotta A, Biasiolo A, Tono N, Franzosi L, Pontisso P, Fassina G, Beneduce L. SCCA-IgM usefulness to monitor patients with cirrhosis is not affected by interfering IgM's. Dig Liver Dis. 41(5):A11. 2009. doi: 10.1016/j.dld.2009.02.031
56. Zuin J, Veggiani G, Pengo P, Gallotta A, Biasiolo A, Tono N, Gatta A, Pontisso P, Toth R, Cerin D, Frecer V, Meo S, Gion M, Fassina G, Beneduce L. Evaluation of the analytical specificity of SCCA-IgM assay for monitoring patients with cirrhosis. Int J Biol Markers. 24(3):209. 2009.
55. Agostini M, Biasiolo A, Pucciarelli S, Maier D, Bedin C, Enzo M, Galdi F, Maretto I, Nitti D, Gatta A, Pontisso P. Matrix metalloproteinase 9 (MMP9)-IgM complex: an emerging novel biomarker in colorectal cancer. Gut. 57:A360. 2008.
54. Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer. 8:200. 2008. doi: 10.1186/1471-2407-8-200
53. Beneduce L, Pesce G, Gallotta A, Zampieri F, Biasiolo A, Tono N, Boscato N, Gatta A, Pontisso P, Fassina G. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma. Eur J Clin Invest. 38(8):571-7. 2008. doi: 10.1111/j.1365-2362.2008.01985.x
52. Beneduce L, Pesce G, Gallotta A, Zampieri F, Biasolo A, Tono N, Pontisso P, Fassina G. Hepatocellular carcinoma induces specific IgM-biomarkers immune complexes. Dig Liver Dis. 40(5):A32. 2008. doi: 10.1016/j.dld.2007.12.083
51. Biasiolo A, Chemello L, Quarta S, Cavalletto L, Bortolotti F, Caberlotto C, Beneduce L, Bernardinello E, Tono N, Fassina G, Gatta A, Pontisso P. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. J Viral Hepat. 15(4):246-249. 2008. doi: 10.1111/j.1365-2893.2007.00935.x
50. Biasiolo A, Tono N, Beneduce L, Zuin J, Gatta A, Fassina G, Pontisso P. Vascular endothelial growth factor (VEGF)-IgM complex for the diagnosis of hepatocellular carcinoma. Gut. 57:A145. 2008.
49. Biasiolo A, Tono N, Quarta S, Beneduce L, Gatta A, Fassina G, Pontisso P. Squamous cell carcinoma antigen (SCCA)-IgM complex: SCCA1-IgM and SCCA-IgM compared to total SCCA-IgM for diagnosis of hepatocellular carcinoma. Gut. 57:A147. 2008.
48. Bucca E, Beneduce L, Leon A, Fabricio A, Michilin S, Steffan A, Durante C, Bellucco C, Rizzo A, Berlanda G, Perasole A, Zampieri F, Zuin J, Fassina G, Gion M. The combination of free CA15.3 and CA15.3-IgM complexes enhances discrimination between healthy subjects and breast cancer patients. Ann Oncol. 19(59):ix95. 2008. doi: 10.1093/annonc/mdn617
47. Cagol M, Ruol A, Biasiolo A, Zanchettin G, Tono N, Castoro C, Alfieri R, Pontisso P, Ancona E. Serum squamous cell carcinoma antigen-IgM (SCCA-IgM) immunocomplex: a new biomarker. Gut. 57:A113. 2008.
46. Calabrese F, Giacometti C, Lunardi F, Valente M. Morphological and molecular markers in idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2(4):505-520. 2008. doi: 10.1586/17476348.2.4.505
45. Calabrese F, Lunardi F, Giacometti C, Marulli G, Gnoato M, Pontisso P, Saetta M, Valente M, Rea F, Perissinotto E, Agostini C. Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibrosis: clinicopathological correlations. Thorax. 63(9):795-802. 2008. doi: 10.1136/thx.2007.088583
44. Gallotta A, Pengo P, Beneduce L, Fassina G. Factors affecting biochip design for cancer early detection. NanotechIT. 10:33-7. 2008.
43. Guido M, Roskams T, Pontisso P, Fassan M, Thung SN, Giacomelli L, Sergio A, Farinati F, Cillo U, Rugge M. Squamous cell carcinoma antigen in human liver carcinogenesis. J Clin Pathol. 61(4):445-7. 2008. doi: 10.1136/jcp.2007.051383
42. Hussein MM, Ibrahim AA, Abdella HM, Montasser IF, Hassan MI. Evaluation of serum squamous cell carcinoma antigen as a novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients. Indian J Cancer. 45(4):167-72. 2008. doi: 10.4103/0019-509X.44666
41. Plebani M. Epatocarcinoma - Biomarcatori Sierologici. . In La scienza nascosta che salva le vite. Vol. 2: I biomarcatori (p. 103). Libreria Internazionale Cortina Padova. 2008.
40. Vidalino L, Quarta S, Baesso I, Fassina G, Gatta A, Pontisso P, Doria A. Squamous cell carcinoma antigen (SCCA) expression and CD27+ memory B lymphocytes in patients with chronic hepatitis C and systemic lupus erythematosus (SLE). Clin Exp Rheumatol. 26:S83. 2008.
39. Beneduce L, Prayer-Galetti T, Giustinian AMG, Gallotta A, Betto G, Pagano F, Fassina G. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients. Cancer Detect Prev. 31(5):402-7. 2007.
38. Cavalletto L, Caberlotto C, Calabrese F, Pontisso P, Bernardinello E, Biasiolo A, Giacometti C, Gottardo A, Gatta A, Chemello L. Clinical significance of serum and liver tissue SCCA in chronic hepatitis C. Dig Liver Dis. 39(3):A18. 2007. doi: 10.1016/j.dld.2006.12.067
37. Fassan M, Pennelli G, Pelizzo MR, Rugge M. Primary squamous cell carcinoma of the thyroid: immunohistochemical profile and literature review. Tumori. 93(5):518-21. 2007.
36. Giannelli G, Antonaci S. Hepatocellular carcinoma: tumoral or peritumoral disease?. Recenti Prog Med. 98(1):23-8. 2007.
35. Giannelli G, Fransvea E, Trerotoli P, Beaugrand M, Marinosci F, Lupo L, Nkontchou G, Dentico P, Antonaci S. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta. 383(1-2):147-52. 2007. doi: 10.1016/j.cca.2007.05.014
34. Giannelli G, Iannone F, Fransvea E, Chialà A, Lapadula G, Antonaci S. Squamous cellular carcinoma immunocomplex is increased in scleroderma patients with lung fibrosis. Clin Exp Rheumatol. 25:794-5. 2007.
33. Parenti A, Porzionato A, Pizzi S, Guzzardo V, Fassina G, Macchi V, Ninfo V, De Caro R. Expression pattern of squamous cell carcinoma antigen in oesophageal dysplasia and squamous cell carcinoma. Histol Histopathol. 22(9):989-95. 2007. doi: 10.14670/HH-22.989
32. Turato C, Ruvoletto M, Biasiolo A, Quarta S, Tono N, Cavalletto L, Chemello L, Merkel C, Gatta A, Pontisso P. HFE, TGF-BETA1 and squamous cell carcinoma antigen-1 polymorphisms and liver disease stage in chronic HCV infection. Dig Liver Dis. 39(3):A27. 2007. doi: 10.1016/j.dld.2006.12.090
31. Vidalino L, Quarta S, Baesso I, Bernardinello E, Ruvoletto M, Frezzato F, Trentin L, Fassina G, Cavalletto L, Chemello L, Gatta A, Pontisso P. Squamosus cell carcinoma antigen (SCCA) expression and CD27+ memory B lymphocytes in patients with chronic hepatitis C. J Hepatol. 46:S179. 2007. doi: 10.1016/S0168-8278(07)62069-8
30. Wright LM, Kreikemeier JT, Fimmel CJ. A concise review of serum markers for hepatocellular cancer. Cancer Detect Prev. 31(1):35-44. 2007.
29. Beneduce L, Gallotta A, Marino M, Fassina G. Des-gamma-carboxy prothrombin-IgM immune complexs as novel biomarker for hepatocellular carcinoma. J Hepatol. 44:S96. 2006. doi: 10.1016/S0168-8278(06)80241-2
28. Beneduce L, Gallotta A, Marino M, Fassina G. Improvement of sensitivity for liver cancer detection by simultaneous evaluation of SCCA-IgM, AFP-IgM complexes and free AFP. J Hepatol. 44:S97. 2006. doi: 10.1016/S0168-8278(06)80242-4
27. Beneduce L, Prayer-Galetti T, Marcello Grimani Giustinian A, Gallotta A, Fracalanza S, Betto G, Artibani W, Pagano F. The occurrence of Prostate Specific Antigen-IgM immune complexes (IC) as novel serum biomarker for prostate cancer. Eur Urol Suppl. 5(2):163. 2006. doi: 10.1016/S1569-9056(06)60568-X
26. Giacometti C, Lunardi F, Marulli G, Loy M, Rea F, Agostini M, Saetta M, Valente M, Calabrese F. Idiopathic pulmonary fibrosis: molecular and proteic detection of SCCA and TGF-beta1. Mod Pathol. 19(S3):166. 2006. doi: 10.1038/sj.modpathol.3800894
25. Giannelli G, Antonaci S. New frontiers in biomarkers for hepatocellular carcinoma. Dig Liver Dis. 38(11):854-9. 2006. doi: 10.1016/j.dld.2006.05.007
24. Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E, Boscato N, Fassina G, Cavalletto L, Gatta A, Chemello L. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer. 119(4):735-40. 2006. doi: 10.1002/ijc.21908
23. Quarta S, Caberlotto C, Beneduce L, Marino M, Fassina G, Tono N, Cavalletto L, Chemello L, Gatta A, Pontisso P. Monitoring SCCA-IgM complex predicts HCC development in cirrhotic patients. J Hepatol. 44:S107. 2006.
22. Quarta S, Vidalino L, Ruvoletto M, Barbera MD, Calabrese F, Valente M, Beneduce L, Gatta A, Fassina G, Pontisso P. SCCA over-expression induces cell proliferation and down-regulation of the adhesion system. J Clin Virol. 36:S193. 2006.
21. Vidalino L, Quarta S, Baesso I, Cavasin L, Bernardinello E, Ruvoletto M, Frezzato F, Trentin L, Fassina G, Cavalletto L, Chemello L, Gatta A, Pontisso P. Deregulation of squamous cell carcinoma antigen (SCCA) expression in B lymphocytes in patients with chronic hepatitis C. J Clin Virol. 36:S28. 2006.
20. Vidalino L, Quarta S, Baesso I, Cavasin L, Bernardinello E, Trentin L, Fassina G, Cavalletto L, Chemello L, Gatta A, Pontisso P. SCCA expression in PBMCs in patients with chronic hepatitis C. Dig Liver Dis. 38:854-9. 2006.
19. Beneduce L, Castaldi F, Marino M, Pontisso P, Fassina G. Comparison of free and IgM-complexed squamous cell carcinoma antigen in hepatocellular carcinoma. J Hepatol. 42:89. 2005.
18. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Benvegnù L, Calabrese F, Gatta A, Pontisso P, Fassina G. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer. 103(12):2558-65. 2005. doi: 10.1002/cncr.21106
17. Castaldi F, Marino M, Beneduce L, Belluco C, De Marchi F, Mammano E, Nitti D, Lise M, Fassina G. Detection of circulating CEA-IgM complexes in early stage colorectal cancer. Int J Biol Markers. 20(4):204-8. 2005.
16. Fassina G, Miertus S. Combinatorial chemistry and technologies: principles methods and applications. Combinatorial chemistry and technologies (second edition), Giorgio Fassina and Stanislav Miertus Editors. CRC Press, Boca Raton, FL pp 1-5. 2005.
15. Giannelli G, Marinosci F, Sgarra C, Lupo L, Dentico P, Antonaci S. Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma. Int J Cancer. 116(4):579-83. 2005. doi: 10.1002/ijc.20847
14. Giannelli G, Marinosci F, Trerotoli P, Volpe A, Quaranta M, Dentico P, Antonaci S. SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int J Cancer. 117(3):506-9. 2005. doi: 10.1002/ijc.21189
13. Marino M, Beneduce L, Palomba D, Fiordelisi A, Fassina G. Combinatorial proteomic. Combinatorial chemistry and technologies (second edition), Giorgio Fassina and Stanislav Miertus Editors. CRC Press, Boca Raton, FL pp 523-38. 2005.
12. Quarta S, Caberlotto C, Beneduce L, Castaldi F, Marino M, Fassina G, Tono N, Cavalletto L, Chemello L, Gatta A, Pontisso P. Serum SCCA-IgM complexes increase over time and HCC development in cirrhotic patients. Dig Liver Dis. 37:A38-A39. 2005.
11. Quarta S, Vidalino L, Ruvoletto M, Della Barbera M, Calabrese F, Valente M, Marino M, Beneduce L, Gatta A, Fassina G, Pontisso P. HCC invasiveness induced by SCCA is associated with nuclear beta-catenin accumulation. J Hepatol. 42:132. 2005.
10. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Pontisso P, Fassina G. Circulating squamous cell carcinoma antigen-IgM complexes as novel biomarkers for hepatocellular carcinoma. Dig Liver Dis. 36:A2-A3. 2004.
9. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Pontisso P, Fassina G. Serological detection of squamous cell carcinoma antigen-IgM complexes in hepatocellular carcinoma. J Hepatol. 40(51):77. 2004. doi: 10.1016/S0168-8278(04)90244-9
8. Beneduce L, Castaldi F, Marino M, Tono N, Gatta A, Pontisso P, Fassina G. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers. 19:155-9. 2004.
7. Pontisso P, Calabrese F, Benvegnù L, Belluco C, Ruvoletto M, Marino M, Beneduce L, Valente M, Nitti D, Alberti A, Gatta A, Fassina G. Squamous cell carcinoma antigen variants overexpression in hepatocellular carcinoma. Proceedings 11th International Symposium on Viral Hepatitis & Liver Disease. 445-6. 2004.
6. Pontisso P, Calabrese F, Benvegnù L, Lise M, Belluco C, Ruvoletto MG, Marino M, Valente M, Nitti D, Gatta A, Fassina G. Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. Br J Cancer. 90:833-7. 2004. doi: 10.1038/sj.bjc.6601543
5. Pontisso P, Fassina G, Quarta S, Ruvoletto M, Tono N, Castaldi F, Nigro A, Marino M, Beneduce L, Gatta A. Nanotecnologie nella diagnostica dell'epatocarcinoma. Atti del 14° Conv. Int. Attualità e Prospettive in Epatologia. 144-8. 2004.
4. Ruvoletto MG, Tono N, Carollo D, Vilei T, Trentin L, Muraca M, Marino M, Gatta A, Fassina G, Pontisso P. Surface expression of squamous cell carcinoma antigen (SCCA) can be increased by the preS1 (21-47) sequence of hepatitis B virus. J Gen Virol. 85:621-4. 2004. doi: 10.1099/vir.0.19130-0
3. Fassina G, Miertus S. Combinatorial technologies in biotechnology. Chemistry Today. 3:28-31. 2003.
2. Calabrese F, Belluco C, Benvegnù L, Ruvoletto M, Valente M, Marino M, Nitti D, Alberti A, Gatta A, Fassina G, Pontisso P. High expression of serine protease inhibitor (SCCA) variants in hepatocarcinoma. Dig Liver Dis. 34(2):155. 2002. doi: 10.1016/S1590-8658(02)80250-X
1. Ruvoletto M, Marino M, Tono N, Gatta A, Fassina G, Pontisso P. Surface expression of squamous cell carcinoma antigen (SCCA) variants can be upregulated by the pre s1 (21-47) sequence of HBV. J Hepatol. 36(S1):83. 2002. doi: 10.1016/S0168-8278(02)80285-9

Xeptagen SpA. - P.IVA 07784560638 - C.F. 03172070272 - Copyright © 2017. All rights reserved. Sitemap. Disclaimer. Privacy Policy.